Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4 CAR+CCR5 ZFN T-cells in HIV-infected Subjects
NCT03617198Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2019
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CD4 CAR+CCR5 ZFN T-cells in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Number of subjects with treatment related adverse events up to 5 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
CD4 CAR+CCR5 ZFN T-cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03617198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617198.